But yet LL has been a failure by all clinical and competitive standards. Many companies with a failed trial claims some trial error -- sample not big enough, should have been longer or different dosing. It is still a FAILURE. CYDY lost another year and now new CoV treatments aren't considered that important. CYDY isn't even starting their U.S. CoV trial even though it was approved -- and it's called a Moderate trial -- how's that going to be necessary or life saving -- it already failed M2M -- nobody claimed that dosing was not adequate. The Brazil trials have been disasters, can't even recruit enough for an interim read. No sure the company has the cash to complete the trial -- can't pay Samsung, surety bond or vulture fund. An aren't starting any new trials
The usual NP-type response -- it's always somebody else's fault.
Market Data 
Markets 
AI
